

January 21, 2022

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Cadilahc

Re.: **Outcome of Board Meeting**

Ref.: **Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated September 9, 2015**

Dear Sir,

We would like to inform that the Board of Directors at their meeting held today i.e. January 21, 2022, based on the recommendation of the Nomination and Remuneration Committee and subject to approval of the members of the Company, have approved the proposal to re-appoint Dr. Sharvil P. Patel (DIN: 00131995) as the Managing Director of the Company for a further period of 5 (five) year w.e.f. April 1, 2022 to March 31, 2027.

The Company will seek approval of members in an extra ordinary general meeting.

Additional details pursuant to regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 along with the brief profile is enclosed as **Annexure-"A"**.

Please take the above on record.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

Dhaival N. Soni

DHAIVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Annexure-“A”

Sr. No.	Particulars	Remarks
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Dr. Sharvil P. Patel (DIN: 00131995) as the Managing Director of the Company for a further period of 5 (five) years w.e.f. April 1, 2022 to March 31, 2027, pursuant to completion of his tenure.
2.	Date of appointment / cessation (as applicable) and term of appointment	Period of 5 (five) years w.e.f. April 1, 2022 to March 31, 2027.
3.	Brief Profile	<p>At present, Dr. Sharvil Patel is the Managing Director of the Company, which is one of the leading global healthcare providers and the 4th largest pharmaceutical company in India. He also officiates as the Chairman on the Board of Zydus Wellness Ltd., which is creating several novel experiences for the health conscious consumers and has a basket of niche products and iconic brands such as Sugar Free, Everyuth, Nutralite, Complian, Glucon D and Nycil. With a specialisation in Chemical and Pharmaceutical Sciences from the University of Sunderland, U.K., and a doctorate also from the same university for his research work in Breast Cancer at Johns Hopkins, Bayview Medical Centre, USA, Dr. Sharvil Patel combines both pharma and research expertise.</p> <p>Dr. Sharvil Patel’s leadership inspires people to look at an expansive canvas of thoughts and ideas while focusing on a well-defined implementation roadmap. He was conferred the ‘40 Under 40 Most Influential Asians’ Award by the Asian Business & Social Forum 2018 (ABSF) and the Young Business Leader ‘40 under Forty’ Award by ET Now in 2017. Recently he has also been conferred the ‘The Economic Times Most Promising Business Leaders of Asia 2020-21’ Award, ‘GenNext Entrepreneur of the Forbes India Leadership Awards (FILA) 2020-21’ by the Forbes India and ‘Young Turks Award’ by India Pharma Awards 2021.</p> <p>The Company is the first Indian pharma company to launch its own patented NCE-Lipaglyn, the novel drug to be approved for the treatment of diabetic dyslipidemia. The group is also the first in the world to announce a treatment for non-cirrhotic NASH, an unmet healthcare condition globally. Supporting the nation in the fight against the novel Coronavirus, Zydus Cadila is at the forefront manufacturing therapies and lifesaving drugs, exploring new therapy options through research, discovering vaccines and manufacturing diagnostic kits. The company also received the emergency use authorization for the world’s first DNA plasmid vaccine ZyCoV-D.</p>



Sr. No.	Particulars	Remarks
4.	Disclosure of relationships between directors (in case of appointment of a director)	Dr. Sharvil P. Patel is the son of Mr. Pankaj R. Patel (Chairman of the Company).
5.	Information as required pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/ 24, dated June 20, 2018.	Dr. Sharvil P. Patel is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

